Clinical trials: Nicotinamide
Covid19, Long COVID-19
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
- Conditions
- Covid19, Long COVID-19, Post-COVID-19 Syndrome
- Trial name
- NCT04604704
- Testing
- Naltrexone, NAD+
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- AgelessRx
NAD+ Bioavailability, NAD+ Safety
A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults
The goal of this clinical trial is to assess the absorption, safety, and efficacy of an NAD+ supplement in healthy adults. The main question it aims to answer is: What is the change in NAD+ levels in whole blood from baseline to…
- Conditions
- NAD+ Bioavailability, NAD+ Safety, NAD+ Efficacy
- Trial name
- NCT07692633
- Testing
- NAD+
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Reus Research
Safety: Healthy Subjects
A Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects.
This study will investigate the safety, tolerability and potential health benefits of the dietary supplement, Basis. There will be two doses of Basis compared to a placebo.
- Trial name
- 15BSHE (NCT02678611)
- Testing
- Basis 250, Basis 500
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Elysium Health
Postoperative Prevention of Tumor
The Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucleotide (Vital NAD)
The main purpose of this study is to explore the PK/PD changes of NMN and DC cells after oral NMN combined with DC cells injection in patients after tumor surgery, and evaluate the biological age of adults, TCR diversity, SiRT1…
- Trial name
- NCT06036355
- Testing
- Oral NMN combined with DC cell vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Hypercholesteremia, Hyperlipidemia
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
This is a 12-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the efficacy of MK0524 to improve the tolerability of extended-release niacin.
- Trial name
- NCT00376584
- Testing
- MK-0524A, ER Niacin
- Volunteers
- 825 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia
To assess the efficacy and safety of Nidadd (extended-release niacin) in patients with hyperlipidemia.
- Trial name
- NCT00244231
- Testing
- Nidadd
- Volunteers
- 70 people
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Dyslipidemia
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
The purpose of this study is to test the effect of MK0524A (niacin (+) laropiprant) on lowering bad cholesterol and raising good cholesterol.
- Trial name
- NCT00664287
- Testing
- niacin (+) laropiprant
- Sponsor
- Merck Sharp & Dohme LLC
Bioavailability
A Study Investigating the Effects of Niagen™ in Healthy Adults.
This study will evaluate the effect of repeated doses of Niagen™ on Niagen™ metabolite concentrations in blood, urine and muscle. There will be 3 doses of Niagen™ compared to a placebo.
- Trial name
- 15NRHC (NCT02712593)
- Testing
- Niagen™ 100, Niagen™ 300, Niagen™ 1000
- Where
- Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
NAD
Method Optimization for the Quantification of the NAD
Method optimization for the quantification of the NAD metabolome in human whole blood, and evaluation of baseline inter and intra-subject variability.
- Trial name
- NCT05561712
- Testing
- Laboratory method validation
- Where
- Switzerland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Aging
Evaluate the Efficacy and Safety of Uthever NMN(Nicotinamide Mononucleotide, a Form of Vitamin B3)
This will be a multi-center, two arm study in 66 healthy adults. Subjects will complete a screening visit (V1, Day -7) to determine eligibility for the study based on Inclusion \& Exclusion Criteria, patient history and safety…
- Trial name
- NMN (NCT04228640)
- Testing
- NMN
- Where
- 2 sites in India
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- EffePharm LTD
Dyslipidemia
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)
This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.
- Trial name
- NCT00111891
- Testing
- niacin (+) laropiprant
- Volunteers
- 575 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Skin Care
A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.
This study aims to determine the local cutaneous and ocular tolerance of 3 developmental skin-care products; a serum, a lotion, and a cream in healthy female subjects with clinically evaluated sensitive facial skin for 21 days.
- Trial name
- NCT04557371
- Testing
- Serum, Lotion, Cream
- Where
- Germany
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Flushing
Effect of MK0524A on Flushing Caused by Niacin (0524A-056)
The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.
- Trial name
- NCT00533611
- Testing
- MK0524A, /Duration of Treatment : 4 Weeks, Comparator : niacin /Duration of Treatment : 1 Weeks
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
The study will evaluate the use of extended release niacin/laropiprant (ERN/LRPT) combination tablets in a primary prevention population currently not taking or eligible for lipid-modifying therapy (LMT); the population will…
- Trial name
- NCT01414166
- Testing
- ERN/LRPT
- Volunteers
- 244 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Mixed Dyslipidemia
Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)
This survey is being conducted to assess the safety and efficacy of niacin (+) laropiprant (TREDAPTIVE) in usual practice in Korea according to the new product re-examination regulations of the Korean Food and Drug Administration.
- Trial name
- NCT01228019
- Testing
- Niacin (+) laropiprant
- Volunteers
- 1,166 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01335997
- Testing
- ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM)
- Volunteers
- 1,139 people
- Sponsor
- Merck Sharp & Dohme LLC
Physical Activity, Muscle Recovery
Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity
The purpose of this study is to evaluate the effect of NMN supplementation (250 and 500 mg/day over 38 days) compared to placebo in healthy volunteers with moderate physical activity on muscle recovery, physical capacity…
- Trial name
- NCT04664361
- Testing
- Nicotinamide mononucleotide
- Where
- France
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Seneque SA
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
This is a multicenter, randomized, double-blind, placebo-controlled study in participants with primary hypercholesterolemia or mixed dyslipidemia, and elevated low density lipoprotein-cholesterol (LDL-C) to assess the efficacy…
- Trial name
- NCT01274559
- Testing
- Extended-release niacin/laropiprant (ERN/LRPT)
- Volunteers
- 1,173 people
- Sponsor
- Merck Sharp & Dohme LLC
Gallstone Disease, Obstructive Jaundice
Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice
Obstructive jaundice is observed in 10-80 % of gallstone disease cases. The conventional tactics for the management of patients with obstructive jaundice is to remove biliary hypertension by using endoscopic or minimally invasive…
- Trial name
- NCT05928286
- Testing
- Remaxol
- Where
- 9 sites in Russia
- Volunteers
- 286 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Gout Disease
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including…
- Trial name
- NCT07889284
- Testing
- Combined metabolic activators, Collagen and maltodextrin
- Where
- 12 sites in Turkey (Türkiye)
- Volunteers
- 336 people
- Sponsor
- ScandiBio Therapeutics AB